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Abstract
Background: The Stop TB Partnership target for tuberculosis is to have reduced the prevalence of tuberculosis by 50%
comparing 2015 to 1990. This target is challenging as few prevalence surveys have been conducted, especially in high
burden tuberculosis and HIV countries. Current tuberculosis control strategies in high HIV prevalent settings are therefore
based on limited epidemiological evidence and more evidence is needed from community-based surveys to inform
improved policy formulation.
Methods and Findings: 8044 adults were sampled from 2 sub-districts (wards) in Lusaka province, Zambia. Questionnaires
were used to screen for symptoms, respiratory samples were obtained for culture and oral secretions collected for HIV
testing. 79 individuals were found to have Mycobacterium tuberculosis in their sputum, giving an adjusted overall
prevalence of tuberculosis of 870/100,000 (95% CI 570–1160/100,000). The adjusted overall prevalence of HIV was 28.61%
(95% CI 26.04–31.19). HIV- infection was significantly associated with prevalent tuberculosis (Adj OR 2.3, 95% CI 1.42–3.74)
and the population attributable fraction of HIV for prevalent tuberculosis was 36%. Symptoms such as prolonged cough (adj
OR 12.72, 95% CI 7.05–22.94) and fever (Adj OR 2.04, 95%CI 1.23–3.39), were associated with prevalent tuberculosis, but 8
(10%) individuals with prevalent tuberculosis denied having any symptoms at all and only 34 (43%) would have been
classified as a TB suspect by current guidelines.
Conclusions: Undiagnosed tuberculosis is a challenge for tuberculosis control and new approaches are needed if we are to
reach international targets. Epidemiological studies can inform screening algorithms for both detection and prevention of
active tuberculosis.
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Introduction
Tuberculosis is one of the major causes of morbidity and
mortality in poor countries, especially sub-Saharan Africa [1], and
is therefore included as one of the diseases covered by the sixth
Millennium Development Goal. The target for tuberculosis is to
have halted and reversed the spread of tuberculosis by 2015 [2],
achievable, according to the Stop TB partnership, only if
prevalence of tuberculosis is halved by 2015 compared to 1990
figures. In order to meet this target the Stop TB Partnership has
published a new Stop TB Strategy [3]. This strategy acknowledges
that DOTS is still the backbone of global tuberculosis control (with
targets of finding 70% of new smear positive cases of tuberculosis
and curing 85% of them) but that there needs to be increased
effort to address the convergence of tuberculosis and HIV,
particularly in sub-Saharan Africa where many patients notified
with TB are also co-infected with HIV. A WHO TB/HIV policy
lays out the activities that national TB and HIV programmes are
being encouraged to scale up [4].
Zambia is an example of a country highly affected by HIV with
an estimated national HIV prevalence of 17% in adults [5].
Tuberculosis notifications have increased 5- fold in the last 20
years, mainly due to the HIV epidemic. The national TB control
programme has expanded DOTS to 100% of government health
facilities and has achieved a 76% cure rate and yet has an
estimated case detection rate of new smear positive cases of only
53% [6]. Of patients notified with tuberculosis the HIV prevalence
is approximately 70%. Zambia has also been in the forefront of
rolling out anti-retroviral therapy (ART) to the HIV-infected
population. ART became more widely available from 2004 and
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now more than 120,000 individuals ( representing 50% at need)
are receiving it [5].
Neither the target set for monitoring the Millennium Develop-
ment Goals, nor the case detection rate, key to DOTS, is easy to
measure [7]. Few case-finding surveys have been conducted in
Africa and most of these were in the pre-HIV era
[8,9,10,11,12,13]. These early surveys gave invaluable information
about the epidemiology of TB, without HIV, and lead to the
formulation of the current TB control strategy- DOTS, which
relies on passive case-finding by investigating only those
individuals presenting to the health services with symptoms of
prolonged cough or haemoptysis. However, large population-
based surveys have not been conducted during the period since the
HIV epidemic has lead to such dramatic increases in the incidence
of tuberculosis.
Two prevalence surveys from occupational settings have
suggested that HIV may not have such a profound effect on the
prevalence of tuberculosis as it does on the incidence [14,15].
Individuals with HIV have also been shown to be less infectious
than those without dual infection [16,17], but transmission at
community level is likely to be directly related to the prevalence of
disease in the population. Population-based studies of the risk of
transmission of tuberculosis in high HIV prevalent settings have
drawn contrasting conclusions with stable risk in East Africa [18]
and increased transmission in the gold mines of South Africa [19].
Two recent prevalence studies have been conducted in South
Africa. One, from a low HIV prevalence community [20], and
another study from a community with high burden of HIV and
tuberculosis [21], both in Cape town, indicated that many cases of
tuberculosis were not detected by the routine tuberculosis control
programme and were only detected by door-to–door screening
associated with the surveys. These surveys and a study from a
clinical trial site in Tanzania [22] have found that the clinical
algorithm used to identify tuberculosis suspects for further
investigation, the basis of the DOTS strategy for case-finding,
may miss a significant proportion of cases of active tuberculosis.
In this study we present the results of a large community-based
tuberculosis and HIV prevalence survey in two communities in
Lusaka Province, Zambia. The aim of the study is to determine the
prevalence of tuberculosis, HIV and respiratory symptoms and to
consider the implications for the new Stop TB Strategy.
Methods
Ethics Statement
Ethical approval for the study was obtained from the research
ethics committees of the University of Zambia, the London School
of Hygiene and Tropical Medicine and Stellenbosch University.
Community leaders, district and local health staff and neighbour-
hood health committees agreed to the study taking place. All
individuals involved in the study gave written informed consent.
Study Sites
The study was conducted in 2 sites (each a political division
called a ward) in 2 districts of Lusaka Province of Zambia. The
sites were purposively selected to represent rural and urban
communities. The rural community has a major road running
through it, but otherwise consists of small villages with subsistence
farming as the major occupation. The urban community is
representative of many such urban settlements in the major towns
of Zambia, but not as crowded as the high-density areas in the
capital, Lusaka. The majority of the population of this community
were employed in small-scale business and informal trading. Each
site was served by 1 TB diagnostic centre. The TB notification
rates for 2004 were 275/100,000 in the rural site and 438/100,000
in the urban site. The total population according to the 2000
census of the two communities was 17,393 for the rural site and
10,963 for the urban site.
Sample size calculation
In 2004 WHO estimated the tuberculosis prevalence for
Zambia to be 707/100,000[23]. Assuming the prevalence of
tuberculosis to be 1000/100,000 among adults we aimed to
sample 5000 adults in each site that would give an estimate of
prevalence with 95% certainty that the true population prevalence
lies somewhere between 810 and 1,190/100,000.
Sampling strategy
Census maps containing standard enumeration areas were
obtained for both of the survey sites. Each standard enumeration
area contained between 300 and 2000 adults according to the
2000 census.
As the study was conducted in 2005, five years after the last
census, the enumeration data was not considered to be adequate
for use in sampling and therefore equal weight was given to each
standard enumeration area. All standard enumeration areas within
the ward were then listed and assigned a random order. Sampling
started with the first randomly assigned enumeration area and all
households were visited. All adults$15 years were enumerated. If
adults were not present at the time of enumeration two subsequent
appointments were made before the adult was recorded as absent.
In the peri-urban area there were 12 enumeration areas and all of
these were needed to enumerate 4380 adults. In the rural area
there were 22 enumeration areas and 12 were used enumerating
4434 adults.
Following standardised training, research assistants interviewed
study participants using a structured paper questionnaire record-
ing socio-economic data (asset register and the number of meals
eaten per day), present respiratory symptoms, health seeking
behaviour and history of tuberculosis and obtained a spot sputum
sample either spontaneously, if the individual was able to, or
assisted by simple breathing techniques. Any sample produced,
whether it was true sputum or a salivary sample was accepted and
sent for culture. An oral fluid sample was also obtained for HIV
testing, according to the manufacturer’s guidelines (BionorTM
HIV1&2 Test). All individuals were encouraged to attend for
counselling and HIV testing using rapid tests on whole blood at
the local health centre, where infrastructure and human resource
was strengthened to cope with demand.
Laboratory procedures
All sputum samples were labelled by barcode only and
transported in cool boxes to the National TB reference laboratory
(Chest Diseases Laboratory, Lusaka) on the same day of collection.
A direct sputum smear was made and stored unstained. This
smear was stained using a standard ZN carbol fuschin method and
was examined by light microscopy and graded only if the
mycobacteria grew on culture (see below).
Samples were decontaminated using the NAOH-NALC
decontamination method (BBLTM MycoPrepTM KIT [BD]). Each
sample was inoculated onto both a broth (BBLTM MGITTM 960
[BD]) and solid media (Lo¨wenstein Jensen (LJ) [BD]) and
incubated at 37uC either in the automated MGIT960 or a
standard incubator for a maximum period of 42 days for MGIT
and 56 days for LJ. The remainder of decontaminated sample was
stored at 220uC and re-decontaminated if the original culture
became contaminated. If mycobacteria grew, confirmed by ZN
staining of the culture growth, then the original direct smear was
ZAMSTAR TB/HIV Survey
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stained and examined. ZN positive cultures were archived in 20%
glycerol at 220uC and a DNA sample was obtained for
identification by boiling at 96uC for 15 minutes.
Identification of the positive mycobacterial cultures as either
M.tuberculosis or non-tuberculous mycobacteria (NTM) was done
using the Genotype Mycobacteria CM assay (HAIN, Life Science)
performed according to manufacturer’s instructions.
Oral fluid samples were transported in a cool box to a central
laboratory and tested for HIV according to Bionor protocol
(BionorTM HIV1&2 Test) within 3 days of collection.
Laboratory Quality Assurance: All stained sputum smears from
individuals with a positive culture were sent to laboratory staff at
Stellenbosch University where they were re-read in a blinded
manner by 2 individuals. Any discrepancy between the Zambian
and South African readers was rechecked by a third panel of
readers and a final smear result agreed on.
Positive (M.tuberculosis H37RV stock strain) and negative
(phosphate buffer alone) culture controls were regularly included
to monitor the culture process.
Laboratory cross-contamination was investigated in any case
where 2 samples processed on the same day grew M. tuberculosis.
On these samples spoligotyping was performed [24] and if they
had identical spoligopatterns IS6110 RFLP typing was used to
subtype [25].
Follow up
All individuals with a culture positive for Mycobacteria were
revisited. Trained clinicians repeated a questionnaire for symp-
toms and examined the TB suspect. Two further sputum samples
(spot and early morning sample) were collected for smear and
culture and the TB suspect was transported to the tertiary referral
hospital for chest x-ray examination. Any individual suspected or
confirmed to have clinical TB according to algorithm (Fig. 1) was
started on TB treatment at the local TB diagnostic centre.
Counselling and HIV testing were offered to all those found to
have TB.
Data handling
At the first household visits, all household members were
enumerated including name, age and sex. Address and GPS
coordinates were recorded to ensure possible follow-up at a later stage.
Every participant that consented to the study was assigned a
unique study number. Corresponding questionnaire, consent
form, sputum sample and oral swab for each individual were
labelled and anonymously linked using the bar-coded study
number.
Sputum samples were registered electronically at the Zambian
National TB-reference Laboratory. The direct smear, decontam-
inated sputum sample and inoculation tubes of one participant
were all coded with the same original barcode number. Positive,
negative and contaminated culture results were recorded elec-
tronically by scanning the barcode of the culture tube. For positive
culture results paper worksheets were printed to capture results of
confirmatory tests and smear results. HIV-results were recorded in
a register book.
Questionnaire data, laboratory worksheets, HIV results and
follow-up questionnaire were dually entered using tailor-made
Microsoft Visual Basic 6.0 data entry forms and Microsoft Access
2000 databases. Data entry differences were corrected by referring
to the source documents.
Definitions
M. tuberculosis prevalence definition. The prevalence of
Mycobacterium tuberculosis complex was defined as the proportion
of individuals with an evaluable sample (i.e. excluding those
where the sample leaked, was missing or all samples were
contaminated) from which Mycobacterium tuberculosis complex was
grown from the original sputum sample. We will hereafter refer
to this as prevalent M.tuberculosis. We did not exclude those
individuals on tuberculosis treatment and so if M.tuberculosis was
grown, regardless of treatment status, the individual was
classified as having prevalent M.tuberculosis. However if an
individual on tuberculosis treatment was not culture positive
for M.tuberculosis then they were not considered to have prevalent
M.tuberculosis.
Clinical Definitions. Tuberculosis disease was defined
according to the algorithm (Fig. 1). Any individual who had
M.tuberculosis isolated from their original culture and had at least
one positive smear ($3 AFB seen) or another culture was
categorised as having bacteriologically confirmed TB disease. An
individual with M.tuberculosis isolated from the original culture and
who was started on TB treatment due to clinical symptoms or X-
ray findings, but did not have any additional microbiological proof
of TB, was categorised as having bacteriologically unconfirmed
TB disease. Any individual with M.tuberculosis isolated from the
original culture but with subsequently negative smears and
cultures, and who did not have signs and symptoms of TB
clinically or on chest x-ray was categorised as having sub-clinical
TB [22].
TB suspect. Any individual coughing for 3 weeks or more, or
with haemoptysis was regarded as a TB suspect according to
international standard definitions at the time of the study.
Data analysis
Stata Version 9.0 was used for statistical
analysis. Primary analysis of TB and HIV point prevalence
and 95% confidence intervals (95%CI) was done using
appropriate generalized linear models with random effects to
control parameter estimates and standard errors for the effect of
clustering at the standard enumeration area. Additionally these
models were applied to perform univariate and multivariate
analyses. Firstly, possible associated risk factors were explored
using univariate regression. Significantly associated risk factors
identified at this stage were then introduced into a respective
multivariate model. Variables were retained in the final model if
associated likelihood-ratio test showed a P value,0.2.
The impact of HIV on tuberculosis at community level,
assuming causality was estimated by calculating the population
attributable fraction.
Sensitivities and specificities of the different screening algo-
rithms, using culture positive M.tuberculosis as the gold standard,
were calculated with binomial exact confidence intervals.
Results
4048 households with 8814 adults were enumerated from 24
census enumeration areas in the two study sites. 8325 (94.5%)
adults consented to be part of the study, 8044 (91.3% of all
enumerated) had a full culture result available with 281(3.2% of
those enumerated) being excluded for reasons shown in Fig. 2.
Of 8044 evaluable results, 79 had a culture positive for
M.tuberculosis complex giving a crude prevalence of 980/100,000
and an adjusted prevalence of 870/100,000 (95% CI 570–1160).
Of the 79 cases of culture positive M.tuberculosis 22 (28%) were also
smear positive. Of these 8 (36%) were classified as scanty, and 14
(64%) as 1–3+ positive. Since we did not examine the smears of
individuals with negative culture results this is a minimum estimate
of the smear positive prevalence.
ZAMSTAR TB/HIV Survey
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Spoligotyping followed by RFLP analysis of positive cultures
found identical fingerprints in 1 pair of samples giving a potential
cross-contamination rate of less than 2%.
Associations with prevalent M.tuberculosis
The two communities had significantly different prevalence
rates with the more rural community having an adjusted
prevalence of 650/100,000 (95% CI 360–940) and the more
urban community having a prevalence of 1200/100,000 (95% CI
750–1640) (Table 1).
The prevalence of M.tuberculosis was highest in the 35–44 years
age group (adj OR comparing 35–44 years with 15–24 years 3.31,
95% CI 1.67–6.56) but there was no difference seen between the
prevalence in men and women. The prevalence of M.tuberculosis
was significantly higher in HIV positive individuals than those who
were HIV negative (Adj OR 2.30, 95% CI 1.42–3.74).
On univariate analysis there was a significant increased risk of
prevalent M.tuberculosis amongst those who had previously had
TB (Univariate OR 2.98, 95% CI 1.47–6.03). However this
association had significant interaction with HIV status; HIV
negative individuals having an increased risk of prevalent
M.tuberculosis if they had had previous TB compared to the group
who had not had previous TB (OR 8.37, 95%CI 3.60–19.48),
whereas it appeared protective for HIV-positive individuals (OR
0.58, 95%CI 0.05–1.40), and thus it was not included in the final
multivariate model.
Figure 1. Algorithm for Decision on Clinical TB.
doi:10.1371/journal.pone.0005602.g001
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We used a simple asset register and the number of meals eaten
in a day to give a crude indication of socio-economic status. For
any one of these assets there was a trend towards ownership of
assets, and therefore higher socio-economic status, decreasing the
risk of prevalent M.tuberculosis but none was significant.
Of the 79 cases of prevalent M.tuberculosis only 51 (65%, 2
missing data) admitted to having any cough and of these 34 (67%)
had been coughing for more than 3 weeks (definition for being a
TB suspect at the time of this study and needing investigation for
tuberculosis). Having a cough of short duration (,21 days) was a
risk factor for having prevalent M.tuberculosis (adj OR 3.07, 95%CI
1.62–5.81) but coughing for more than 3 weeks provided the
strongest association with prevalent M.tuberculosis (adj OR 12.72,
95% CI 7.05–22.94). All other symptoms were associated with
prevalent M.tuberculosis on univariate analysis, but on multivariate
analysis only fever remained significant in the final model (Adj OR
2.04, 95%CI 1.23–3.39).
Clinical Tuberculosis
Following the algorithm shown in Fig. 1, we determined the TB
disease status of all individuals from whom M.tuberculosis was
isolated. Of the 79 individuals with prevalent M.tuberculosis, 42
(53%) were bacteriologically confirmed to have TB disease with
either subsequent smears or cultures positive for TB, 2 (2.5%) had
clinical signs of TB or chest x-ray changes suggestive of TB (and
they were started on TB treatment) but the diagnosis was not
subsequently confirmed bacteriologically, and 15 (19%) were
categorised as having sub-clinical TB. Of these sub-clinical TB
cases 4 (27%) had no symptoms at the time of sputum submission,
3 (75%) were HIV positive. By the time of follow up the 3 HIV
positive individuals had developed minor symptoms but 2 further
sputum smears and cultures were negative for TB. The HIV-
negative individual remained asymptomatic and further smears
and cultures were negative. This case was one of the pair with the
Figure 2. Flowchart of Individuals within the Study.
doi:10.1371/journal.pone.0005602.g002
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Table 1. Associations with Prevalent M.tuberculosis
Characteristic N TB Adj-Prev1 95% CI Univariate Multivariate
OR 95% CI p OR 95% CI p
Total 8044 79 0.87 0.57–1.16
Community 0.037 0.0209
Rural 4055 28 0.65 0.36–0.94 1.00 1.00
Urban 3989 51 1.20 0.75–1.64 1.86 1.07–3.24 2.06 1.16–3.64
Missing 0
Age 0.000 0.0018
15–24 3244 15 0.41 0.18–0.65 1.00 1.00
25–34 1937 22 1.01 0.51–1.5 2.45 1.26–4.74 1.82 0.91–3.64
35–44 1154 27 2.15 1.20–3.1 5.29 2.79–10.02 3.31 1.67–6.56
45–54 685 8 1.02 0.27–1.78 2.49 1.05–5.91 1.54 0.62–3.81
55–64 357 1 0.25 0.00–0.74 0.60 0.08–4.56 0.31 0.04–2.41
.64 327 3 0.83 0.00–1.8 2.01 0.58–7.03 0.98 0.27–3.57
Missing 340 3
Sex 0.463
Male 3709 39 0.94 0.56–1.32 1.00
Female 4334 40 0.80 0.47–1.13 0.85 0.54–1.32
Missing 1 0
HIV-result ,0.001 0.0007
Negative 5666 36 0.55 0.32–0.79 1.00 1.00
Positive 2297 43 1.65 1.00–2.31 3.03 1.93–4.74 2.30 1.42–3.74
Missing 81 0
Previous TB 0.008
No 7701 70 0.81 0.53–1.08 1.00
Yes 333 9 2.36 0.71–4.01 2.98 1.47–6.03
Missing 10 0
Currently Coughing ,0.001 ,0.001
No 6124 26 0.37 0.20–0.55 1.00 1.00
Yes between 1–21 days 1274 17 1.23 0.56–1.89 3.31 1.78–6.15 3.07 1.62–5.81
Yes.21 days 493 34 6.34 3.71–8.97 18.04 10.60–30.71 12.72 7.05–22.94
Missing duration 153 2
Shortness breath ,0.001
No 6650 44 0.56 0.32–0.79 1.00
Yes 1384 35 2.28 1.31–3.25 4.17 2.64–6.57
Missing 10 0
Fever ,0.001 0.0061
No 6066 37 0.50 0.27–0.72 1.00 1.00
Yes 1962 42 1.92 1.13–2.71 3.91 2.48–6.16 2.04 1.23–3.39
Missing 16 0
Night sweats ,0.001
No 6001 40 0.57 0.33–0.81 1.00
Yes 2018 39 1.73 1.02–2.43 3.07 1.96–4.81
Missing 25 0
Weight loss ,0.001
No 4878 34 0.59 0.33–0.85 1.00
Yes 2868 44 1.36 0.83–1.9 2.33 1.48–3.67
Missing 298 1
Chest pain ,0.001
No 5886 38 0.56 0.33–0.80 1.00
ZAMSTAR TB/HIV Survey
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same fingerprint and may represent laboratory error or contam-
ination.
The remaining 11 (73%) had symptoms at the time of the
original sputum collection but these had resolved or changed by
the time of clinical follow up. Of this group 9 (82%) were HIV-
positive and symptoms were often non-specific e.g. fever and
weight loss. Chest x-rays were not considered to show tuberculosis
and subsequent smears and cultures were negative.
Unfortunately 20 individuals (25%) could not be categorised as
they did not complete the clinical follow up because they had died (4,
20%), moved (5, 25%) refused follow up (3, 15%) could not be found
(4, 20%) or did not complete the follow-up evaluation (4, 20%).
HIV
Overall HIV results are available for 7963 of the 8044
individuals included in this analysis (99%). Adjusted HIV
prevalence was 28.61% (95% CI 26.04–31.19) in the two sites
studied, with no statistical differences being seen between the
urban and rural sites (Table 2). HIV prevalence varied with age
and sex as has been previously demonstrated in Sub-Saharan
Africa being significantly higher in women than in men (Adj OR
1.32 95% CI 1.19–1.47). Having been previously been diagnosed
with TB was significantly associated with being HIV positive. The
number of symptoms and specific symptoms associated with TB
were found more often in HIV positive individuals. The study was
not designed to look for specific risk factors for HIV infection,
however there was a trend towards owning more assets and having
more meals per day, higher socio-economic status, being
protective for HIV (e.g. Adj OR for bicycle ownership 0.79,
95% CI 0.7–0.89).
The HIV prevalence among individuals with prevalent
M.tuberculosis was 55%. Assuming causality, the impact (population
attributable fraction, PAF) of HIV on prevalent TB in these
communities was 36.0%.
We identified a large number of non-tuberculous mycobacteria
(NTM), which will be reported in a separate publication.
Symptoms
Overall 5319 (66%) of the population questioned declared at
least one symptom, and 1920 (23.8%) had a cough. Only 581
(7.2%) met the definition of a suspect who should be further
investigated for tuberculosis. Despite the surprisingly high
proportion of symptomatic individuals in the community, 8 of
the 79 (10%) individuals with M.tuberculosis isolated from their
Characteristic N TB Adj-Prev1 95% CI Univariate Multivariate
OR 95% CI p OR 95% CI p
Yes 2125 40 1.68 1.00–2.35 3.01 1.92–4.72
Missing 33 1
Car 0.158
No 7697 78 0.90 0.59–1.2 1.00
Yes 330 1 0.28 0.00–0.84 0.31 0.04–2.26
Missing 17 0
Bicycle 0.061
No 5639 64 1.00 0.65–1.36 1.00
Yes 2388 15 0.60 0.27–0.92 0.59 0.33–1.05
Missing 17 0
Television 0.927
No 5755 57 0.87 0.55–1.20 1.00
Yes 2272 22 0.85 0.43–1.28 0.98 0.58–1.63
Missing 17 0
Radio 0.399
No 2693 31 0.99 0.55–1.43 1.00
Yes 5339 48 0.81 0.51–1.11 0.82 0.51–1.30
Missing 12 0
Fridge 0.319
No 7031 72 0.91 0.59–1.22 1.00
Yes 984 7 0.61 0.12–1.11 0.67 0.30–1.52
Missing 29 0
Number of meals 0.252
0 96 2 1.28 0.36–2.19 1.00
1 1050 13 1.08 0.55–1.6 0.852 0.63–1.13
2 3152 30 0.91 0.60–1.22
3 or more 3687 33 0.76 0.45–1.07
Missing 59 1
1Adjusted for clustering.
2OR for trend.
doi:10.1371/journal.pone.0005602.t001
Table 1. Cont.
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Table 2. Associations with HIV
Characteristic N HIV Adj. prev1 95% CI Univariate Multivariate
OR 95% CI p OR 95% CI p
Total TB-prevalence
survey
8044
HIV-test done 7963 2297 28.61 26.04–31.19
Community 0.792
Rural 4016 1198 28.94 25.19–32.68 1.00
Urban 3947 1099 28.23 24.34–32.11 0.97 0.74–1.25
Age ,0.001 ,0.001
15–24 3220 630 19.67 17.10–22.25 1.00 1.00
25–34 1919 705 38.51 34.41–42.61 2.56 2.24–2.92 2.38 2.09–2.73
35–44 1138 418 38.75 34.19–43.32 2.58 2.22–3.01 2.37 2.02–2.77
45–54 674 225 35.62 30.63–40.61 2.26 1.88–2.72 2.05 1.69–2.48
55–64 353 123 36.26 30.15–42.36 2.32 1.83–2.95 2.11 1.65–2.70
.64 324 92 30.24 24.24–36.23 1.77 1.36–2.30 1.55 1.18–2.03
Missing 335 104
Sex ,0.001 ,0.001
Male 3670 968 25.97 23.33–28.60 1.00 1.00
Female 4293 1329 30.88 28.05–33.71 1.27 1.15–1.41 1.32 1.19–1.47
TB-culture ,0.001 0.003
No Growth 7562 2153 28.18 25.71–30.63 1.00 1.00
MOTT 322 101 30.60 24.92–36.27 1.12 0.88–1.44 1.13 0.86–1.48
TB 79 43 54.83 43.49–66.18 3.09 1.97–4.85 2.25 1.39–3.66
Previous TB ,0.001
No 7621 2124 27.60 25.19–30.01 1.00 ,0.001 1.00
Yes 333 170 51.78 45.70–57.86 2.82 2.25–3.52 2.31 1.83–2.93
Missing 9 3
TB-Suspect ,0.001 ,0.001
No 7385 2067 27.86 25.57–30.15 1.00 1.00
Yes 578 230 40.53 35.71–45.35 1.76 1.48–2.11 1.44 1.19–1.76
Number of
symptoms
,0.001
0 2685 664 24.84 22.67–27.01 1.00
1 3 2021 561 27.46 25.32–29.60 1.15 1.11–1.18
2 1330 395 30.24 27.98–32.51
3 892 271 33.18 30.61–35.74
4 534 199 36.25 33.22–39.28
5 305 118 39.44 35.83–43.05
6 196 89 42.73 38.46–46.99
Car 0.186
No 7617 2205 28.75 26.16–31.34 1.00
Yes 329 87 25.41 20.21–30.60 0.84 0.65–1.09
Missing 17 5
Bicycle ,0.001 ,0.001
No 5577 1685 29.98 27.76–32.20 1.00 1.00
Yes 2369 605 24.56 22.16–26.97 0.76 0.68–0.85 0.79 0.70–0.89
Missing 17 7
Television 0.011
No 5698 1694 29.66 27.03–32.28 1.00
Yes 2248 598 26.55 23.86–29.25 0.86 0.76–0.97
Missing 17 5
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sputum denied having any symptoms at all, and only 34 (43%)
would be classified as a TB suspect.
Taking any symptom into consideration, the more symptoms an
individual had the more likely they were to have M.tuberculosis
isolated from their sputum (OR for trend 1.71, 95% CI 1.52–1.93)
and the more likely they were to be HIV positive (OR for trend
1.15, 95% CI 1.11–1.18). Apart from cough the symptoms most
associated with a diagnosis of prevalent M.tuberculosis were different
in HIV positive compared to HIV negative individuals. For HIV
negative individuals cough for 1–3 weeks was a risk factor for
prevalent M.tuberculosis (Adj OR 3.96, 95% CI 1.57–10.00) as was
cough for 3 weeks or more (Adj OR 11.18, 95% CI 4.45–28.07)
and fever (Adj OR 2.63, 95% CI 1.23–5.63). For HIV positive
individuals only cough of 3 weeks or more (Adj OR 11.95, 95% CI
5.38–26.56) and chest pain (Adj OR 2.11, 95%CI 1.23–5.63) were
significantly associated with having prevalent M.tuberculosis.
If the standard definition of a TB suspect, i.e. cough for 3 weeks or
more or haemoptysis, is used in these communities it gives a sensitivity
of 43.4% and specificity of 93.1% for the whole population (Table 3).
The sensitivity and specificity compared by HIV status shows higher
values in HIV positive individuals but these are generally not
statistically significant. Modifying the algorithm to include either
cough for more than 3 weeks/haemoptysis or any other 2 symptoms
improves the sensitivity to 74.7%.
Discussion
This paper presents data from a large community based study,
with samples collected from a high proportion of targeted adults.
The estimated prevalence of tuberculosis of 870/100,000 adults is
high, but it is in line with the WHO estimation of a prevalence of
707/100,000.
Few large-scale TB and HIV prevalence surveys have been
conducted in Africa. Previous studies in the pre-HIV era and in
lower HIV prevalence settings have estimated a lower prevalence
of TB but comparisons must be made with caution as differences
in sampling, screening strategies and also the laboratory methods
used, both in the smear and culture procedures, make direct
comparisons difficult [26]. The only other prevalence surveys
where all participants had a TB culture performed show a similar
range of prevalent TB [14,15,20,21], higher in the gold mines of
Characteristic N HIV Adj. prev1 95% CI Univariate Multivariate
OR 95% CI p OR 95% CI p
Radio 0.760
No 2676 775 28.84 25.87–31.80 1.00
Yes 5275 1518 28.47 25.80–31.15 0.98 0.88–1.09
Missing 12 4
Fridge 0.225
No 6964 2028 28.97 26.33–31.61 1.00
Yes 970 262 26.89 23.33–30.45 0.90 0.76–1.07
Missing 29 7
Number of meals ,0.001 0.004
0 95 41 36.67 32.20–41.13 1.00 1.00
1 3 1035 350 33.06 29.87–36.25 0.852 0.80–0.91 0.902 0.84–0.97
2 3127 897 29.64 27.22–32.06
3 or more 3648 994 26.44 24.07–28.81
Missing 58 15
1adjusted for clustering.
2OR for trend.
doi:10.1371/journal.pone.0005602.t002
Table 2. Cont.
Table 3. Sensitivity, specificity and predictive values for
different screening algorithms
Sensitivity Specificity PPV NPV
Any symptom
All 89.9 (81.0–95.5) 34.1 (33.1–35.2) 1.3
(1.0–1.7)
99.7 (99.4–
99.9)
HIV Negative 83.3 (67.2–93.6) 35.8 (34.5–37.1) 0.8
(0.6–1.2)
99.7 (99.4–
99.9)
HIV Positive 95.3 (84.2–99.4) 29.4 (27.5–31.3) 2.5
(1.8–3.4)
99.7 (98.9–
100)
Any Cough
All 67.1 (55.6–77.3) 76.6 (75.6–77.5) 2.8
(2.1–3.6)
99.6 (99.4–
99.7)
HIV Negative 66.7 (49.0–81.4) 77.8 (76.7–78.9) 1.9
(1.2–2.8)
99.7 (99.5–
99.9)
HIV Positive 67.4 (51.4–80.9) 73.1 (71.3–75.0) 4.6
(3.1–6.5)
99.2 (98.6–
99.5)
TB Suspect (Cough 3 weeks or more or haemoptysis)
All 43.0 (31.9–54.7) 93.1 (92.6–93.7) 5.9
(4.1–8.1)
99.4 (99.2–
99.6)
HIV Negative 36.1 (20.8–53.8) 94.0 (93.4–94.7) 3.7
(2.0–6.3)
99.6 (99.4–
99.7)
HIV Positive 48.8 (33.3–64.5) 90.7 (89.5–91.9) 9.1
(5.7–13.6)
98.9 (98.4–
99.3)
TB suspect or any other 2 symptoms
All 74.7 (63.6–83.8) 58.8 (57.7–59.9) 1.8
(1.3–2.3)
99.6 (99.3–
99.7)
HIV Negative 69.4 (51.9–83.7) 61.0 (59.7–62.2) 1.1
(0.7–1.7)
99.7 (99.4–
99.8)
HIV Positive 79.1 (64.0–90.0) 53.0 (51.0–55.1) 3.1
(2.2–4.3)
99.3 (98.6–
99.7)
doi:10.1371/journal.pone.0005602.t003
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South Africa[14] and in a high prevalence township in the
Western Cape [21]- although the confidence intervals surrounding
this estimate are wide due to the small sample size (Table 4).
In this study HIV had a significant effect on the prevalence of
tuberculosis. This contrasts to the two studies conducted in
occupational settings where HIV was found to influence incidence
of disease much more than prevalence [14,15]. This difference
may reflect the better access to medical services afforded to
individuals in such occupational settings. Indeed it is possible that
HIV is having a double effect on TB control services in our
communities; not only are there more TB cases and therefore
increased transmission of disease, but also there is an increasing
burden on over-stretched health services, making effective control
harder to achieve [27]. Our study found many cases of
undiagnosed tuberculosis in the community but it is unclear how
many would have eventually received treatment in the absence of
the survey. In our definition of prevalent tuberculosis we only
included those individuals with a culture positive for M.tuberculosis,
and excluded those individuals who were currently on TB
treatment but whose culture was negative, however 5 of our
prevalent cases reported that they were already on TB treatment
at the time of the survey.
Although tuberculosis was strongly associated with coughing for
3 weeks or more in both HIV negative and HIV positive
individuals, the study demonstrates that many individuals have
culture positive tuberculosis in the absence of symptoms sufficient
to meet the definition of being a TB suspect. This study gives more
insight into the effectiveness of symptom screening at community
level than previous studies. The definition of a TB suspect, i.e.
cough for more than 3 weeks or haemoptysis has a sensitivity of
48.8% in HIV positive individuals, but this can be improved by
considering other symptoms. If any symptom is considered the
sensitivity becomes 95.3% but such a strategy would result in a
very large number of the HIV-positive population requiring
laboratory investigation, requiring significant laboratory expansion
and strengthening. A more practical approach may be to use an
algorithm that includes traditional TB suspects or anyone with at
least 2 other symptoms, this increases the sensitivity to 79.1%
while reducing the burden on the laboratory. If we consider 1000
HIV positive individuals, our data indicate that 476 would be
classified as TB suspects under this scenario and would therefore
require additional laboratory tests to identify a possible 15 cases of
culture positive M.tuberculosis (i.e. 32 individuals would need to be
investigated for every positive case). Since conducting this study
the definition of a TB suspect has been changed to include all
individuals coughing for 2 weeks or more. We did not include this
question in our questionnaire and so are unable to comment on
how this would have performed in this setting.
The findings of this study have significant implications for TB-
HIV activities as are recently highlighted by WHO HIV
departments ‘‘3I’s’’ initiative [28] (Intensified case finding,
Isoniazid preventive therapy and Infection Control) and TB
department (Interim Policy for collaborative TB-HIV activities)
[4]. This study demonstrates a very high burden of both TB and
HIV in these Zambian communities. Intensified case finding for
both TB and HIV could have a significant impact on both
epidemics, especially if treatment for both conditions was
universally available [29]. It may be that community level
approaches could reduce transmission of TB and HIV and despite
logistical challenges would be worthwhile in the long term. The
widespread use of ART may have an impact on the prevalence of
tuberculosis. Mathematical models show that as more HIV-
positive individuals live for longer with some degree of
immunosuppression, the burden of tuberculosis may increase
despite the fact that the incidence of tuberculosis in these
individuals will fall [30]. Our study was conducted at a time
when ART use was low at community level and so does not give
any insight into this but in future ART usage should be recorded
in prevalence surveys.
Isoniazid preventive therapy has been demonstrated to reduce
the risk of HIV-positive individuals developing tuberculosis but
active tuberculosis must be excluded before it is used [31]. What
screening is necessary to exclude tuberculosis has been controver-
sial, however the negative predictive value of a screen is the most
important statistic to give an indication of the proportion of cases
that would be missed by any particular screen. Our data show that
at the community level the negative predictive value of any of the
screens is high and so the number of cases of active tuberculosis that
would be missed is low. If a modified screen consisting of either the
traditional TB suspect definition, or any other 2 symptoms is used,
the negative predictive value in HIV-positive individuals is 99.3%.
In a hypothetical scenario where 1000 HIV-positive individuals
from a similar community to the ones described in this paper are
screened, 524 individuals would be declared free of symptoms
Table 4. Table of Surveys where all participants were cultured
Study
Ref Year Country Population
Number in
analysis Culture method
Culture
prevalence /
10001
Smear
prevalence /
10001
HIV+ve
culture prev
HIV2ve
culture prev
Corbett 2001 S. Africa Miners 1773 LJ 45/1734 9/1734 17/453 28/1281
26.5 5.2 37.5 21.9
Corbett 2002 Zimbabwe Factory workers 4668 LJ/PNB 15/4668 6/4668 5/874 10/3974
3.2 1.3 5.7 2.5
Den Boon2002 S. Africa Community 2608 LJ 26/2608 8/2608 N/a N/a
10 3.1
Wood 2005 S. Africa Community 762 MGIT/PNB/pcr 12/762 6/762 9/174 3/588
15.7 7.9 51.7 5.1
Ayles 2005 Zambia Community 8044 MGIT/LJ/Hain 79/8044 22/8044 43/2855 36/5630
9.8 2.7 15.1 6.4
1Crude prevalence per 1000 population surveyed
doi:10.1371/journal.pone.0005602.t004
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indicating active TB and could potentially be started on isoniazid
preventive therapy. Of these 524, 4 would actually have a culture
positive for TB. All four would have negative sputum smears and
therefore probably represent paucibacillary disease which may
actually respond to mono-therapy with isoniazid although they may
also develop into isoniazid resistant cases. It is not known howmany
such cases it is acceptable to miss and the likelihood of generating
isoniazid resistance in these cases so further research is needed of
large-scale implementation. What is known is that over the next two
years, the isoniazid preventive therapy would prevent about 15 new
cases of tuberculosis [32].
Infection control is the third of the 3I’s. Whilst most of the cases of
prevalent tuberculosis were not smear positive, and therefore not the
most infectious, we have to assume that all of these cases were
capable of transmitting tuberculosis within the community and
especially to other vulnerable individuals, including those with HIV
[33]. Infection control in congregate settings is critical, especially
those where HIV positive individuals spend large amounts of time
such as health centres. It may be that screening of all individuals with
any symptom in these settings would be warranted and that
symptomatic individuals need to be separated from others.
Since this survey was done the WHO definition for tuberculosis
disease has been changed to include all individuals with a single
positive smear or culture, rather than the requirement for at least 2
positive results. This raises interesting questions as 14 of the
individuals that we identified did not have further confirmation of
disease and were not started on TB treatment. There are several
hypotheses to account for what we have termed sub-clinical TB
disease. Some of these cases might represent laboratory contam-
ination or sample mislabelling (as appears to be the case for 1
individual). However our quality control data show that laboratory
contamination was rare and that this could not account for the
other cases identified. All samples were labelled with barcodes and
scanners were used to minimise the chances of transcription errors,
but again this would not account for all the cases identified. It
could be that some of these individuals are transiently excreting
M.tuberculosis but then either self-cure or that we are in fact picking
up primary infections that are being contained and converted into
a latent infection. These hypotheses are difficult to prove although
some of these individuals were symptomatic at first encounter and
when they were re-visited their symptoms had resolved and
cultures were negative. It may be that with expanded use of the
newer, more sensitive liquid culture techniques that we used in this
survey this phenomenon will become more apparent and a recent
study found similar cases in Tanzania [22].
Study Limitations
This was a large and challenging study and therefore the
procedures and questionnaires had to be kept as simple as possible.
Some areas where more detail would have been desirable include
socioeconomic status and more detailed questions about duration
of symptoms. A follow up nested case-control study, specifically
looking at the relationship between socioeconomic status and
prevalent TB, will be reported elsewhere.
The laboratory work involved in this study was extremely time
consuming with relatively few positive results to be found. It would
have been desirable to examine sputum smears on all individuals
but due to a lack of human resources necessary to screen over
8000 slides where more that 99.5% are expected to be negative,
only the slides from the culture positive cases were examined. This
means that we have a minimum estimate of the prevalence of
tuberculosis as some cases may not have grown in culture due to
overly harsh decontamination leading to mycobacterial killing.
Our definition of both smear positivity (agreement by 2 teams of 2
readers) and clinical TB were strict, again minimising the estimate
of prevalence.
Conclusions
This study demonstrates that prevalence of tuberculosis is high
in Zambia and that 36% of all prevalent tuberculosis in these
communities is attributable to HIV. HIV appears to have
overshadowed previously described risk factors for prevalent
tuberculosis such as male sex, urban environment and previous
TB such that it is now the major driving force behind prevalent
TB.
The widely used screening algorithms are not sufficient to find
all cases of tuberculosis, but it may not be feasible to use other
more sensitive screens until better diagnostic tests become
available. Despite this, community case finding for TB and HIV
would detect a large proportion of currently undetected cases
more quickly and therefore limit transmission. Symptom screening
can rule tuberculosis out with a high negative predictive value and
could therefore be useful in exclusion of tuberculosis prior to
provision of isoniazid preventive therapy.
If Zambia, and the rest of Africa, is to meet the Millennium
Development Goals with respect to tuberculosis and HIV we need
to do much more to find cases and treat them, therefore
interrupting transmission at community level.
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